6-35月龄儿童接种全剂量与半剂量四价流感灭活疫苗的免疫原性和安全性:多中心随机双盲阳性对照临床试验
在中国湖北和安徽开展的多中心随机双盲阳性对照试验,纳入3300名6-35月龄儿童,比较全剂量与半剂量四价流感灭活疫苗(QIV)对比半剂量三价疫苗(TIV)的免疫原性和安全性。全剂量和半剂量QIV对所有共同株的血清转换率和几何平均滴度均非劣于半剂量TIV,且全剂量QIV诱导的免疫应答更高,安全性相似,未报告疫苗相关严重不良事件和热性惊厥。
要点
- 全剂量和半剂量QIV对共同株的免疫原性非劣于半剂量TIV。
- 全剂量QIV诱导的免疫应答高于半剂量TIV和半剂量QIV。
- 各组安全性相似,未报告疫苗相关严重不良事件和热性惊厥。
核心结论
- 全剂量和半剂量QIV的免疫原性均非劣于已上市的半剂量TIV。
- 全剂量QIV诱导显著增强的免疫应答,且未观察到新的安全性问题,可能提高6-35月龄儿童的保护。
研究设计与样本
- 多中心、随机、双盲、阳性对照临床试验,在中国湖北和安徽开展。
- 筛选3468人,入组3300名6-35月龄健康儿童,按2:2:1:1比例区组随机分层分配至四组。
- 3289人至少接种一剂:全剂量QIV组1097人、半剂量QIV组1098人、含B Victoria株半剂量TIV组546人、含B Yamagata株半剂量TIV组548人。
- 按0、28天程序接种两剂,免疫前和 second dose后28天采集血样检测血凝抑制抗体。
主要发现
- 全剂量和半剂量QIV对所有共同株的血清转换率和几何平均滴度均非劣于半剂量TIV。
- 全剂量QIV诱导的免疫应答高于半剂量TIV和半剂量QIV。
- 各组安全性特征相似,未报告疫苗相关严重不良事件和热性惊厥。
关键数值与推荐
- 非劣效界值:血清转换率差值的95%置信区间下限≥-10%,几何平均滴度比值的95%置信区间下限≥2/3。
- 主要终点为接种后28天的血清转换率和几何平均滴度。
- 安全性评估持续至末次接种后6个月。
临床怎么用
- 6-35月龄儿童可考虑使用全剂量QIV以获得更高的免疫应答。
- 全剂量QIV的安全性特征与半剂量TIV相似,未报告疫苗相关严重不良事件和热性惊厥。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In children aged 6 to 35 months, the full-dose influenza vaccine (15 μg hemagglutinin per strain) demonstrated superior protection against influenza in children 6 to 35 months compared to the 7.5 μg half-dose formulation. METHODS: A multi-center, randomized, double-blind, active-controlled study was conducted in Hubei and Anhui provinces, China. This study evaluated the immunogenicity and safety of full-dose and half-dose inactivated quadrivalent influenza vaccines (QIVs), compared with half-dose inactivated trivalent influenza vaccines (TIVs), in children aged 6 to 35 months. Children in stable health aged 6 to 35 months were enrolled and randomly allocated to four study groups in a 2:2:1:1 ratio by block randomization stratified by sites. Participants received two doses of either the full-dose or half-dose QIVs, or half-dose TIVs (containing a B Victoria or B Yamagata strain) following a 0, 28-day immunization schedule. Blood samples were collected before vaccination and 28 days after the second dose to test the Hemagglutination inhibition (HI) antibodies. The primary endpoints were the seroconversion rates (SCRs) and geometric mean titers (GMTs) at 28 days post-vaccination. The non-inferiority was defined as the 95 % lower limit confidence interval (LLCI) of SCR difference ≥ -10 % and the 95 % LLCI of GMT ratio ≥ 2/3. Safety was evaluated through to 6 months after the last dose. RESULTS: Between September 16 and October 13, 2023, a total of 3468 individuals screened and 3300 participants were enrolled. 3289 were administered at least one dose of full-dose QIV (n = 1097), half-dose QIV (n = 1098), half-dose TIV (containing a B Victoria) (n = 546) or half-dose TIV (containing a B Yamagata) (n = 548). The full-dose and half-dose QIVs demonstrated non-inferiority to the half-dose TIVs in terms of SCRs and GMTs for all shared strains. Specifically, the full-dose QIV induced higher immune responses compared to the half-dose TIVs and QIV. Safety profiles were similar across all groups, and there was no vaccine related serious adverse events and febrile convulsion reported. CONCLUSION: The immunogenicity of both the full-dose and half-dose QIVs were non-inferior to the licensed half-dose TIVs. Importantly, the full-dose QIV elicited significantly enhanced immune responses and no new safety concerns were observed, which may improve the protection in children aged 6 to 35 months. CLINICAL TRIAL REGISTRATION: Clinicaltrials.gov identifier: NCT06049927.
引用
- Wang L, Li L, Yang W, et al. Immunogenicity and safety of inactivated quadrivalent influenza vaccines in children aged 6-35 months: A multi-center, randomized, double-blind, active-controlled clinical trial. Vaccine. 2025. PMID: 41391373. doi:10.1016/j.vaccine.2025.128113
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。